Sanofi Plans To Add Two NMEs To Phase III In 2004, Bringing Total To Nine
This article was originally published in The Pink Sheet Daily
Executive Summary
Antidepressant saredutant and hyponatremia agent SR 121463 are ready to proceed to final stage of development after successful Phase IIb results. Combined with merger target Aventis, Sanofi's current total would be 12 novel Phase III agents, rivaled only by Pfizer.